What Researchers Did
Researchers conducted a systematic review and meta-analysis to evaluate the effectiveness and safety of hyperbaric oxygen therapy (HBOT) for different inflammatory bowel disease (IBD) phenotypes.
What They Found
HBOT showed varying clinical remission rates across IBD phenotypes, including 87% for ulcerative colitis (n=42), 88% for luminal Crohn's disease (n=8), and 60% for perianal Crohn's disease (n=102). Lower remission rates were observed for pouch disorders at 31% (n=60), while 15% of patients (n=30) experienced minor adverse events.
What This Means for Canadian Patients
Hyperbaric oxygen therapy may be a potential treatment option for certain IBD conditions, particularly ulcerative colitis and luminal Crohn's disease, but its effectiveness varies significantly by phenotype. Patients with IBD should discuss HBOT with their healthcare providers to understand its potential benefits and risks for their specific condition.
Canadian Relevance
This systematic review includes Canadian authors, indicating direct relevance to Canadian research and clinical practice in inflammatory bowel disease.
Study Limitations
The overall quality of the included studies was low, primarily due to the absence of comparator arms and insufficient reporting of interventions or objective outcomes.